Elevance What to Know from ELV’s 2Q Earnings Call and Follow-Up With Management

Research evidence excerpt

Elevance What to Know from ELV’s 2Q Earnings Call and Follow-Up With Management

ng the 2027 growth outlook. These investments are designed to fund

medical cost management, member engagement, provider connectivity, and

integrated capabilities. In our catch-up with management, the company indicated

that these targeted investments would contribute to growth in 2027.

• Individual ACA performance was favorable to expectations, with bronze mix

driving the seasonal shift in earnings contribution.

• ACA Exchange performance developed broadly in line with 2026 pricing,

although membership appears to be coming in ahead of expectations, with ELV

revising enrollment up by ~100K to at least 1M by year end. We would note that

this implies continued enrollment attrition in 3Q/4Q to bridge 2Q’s 1.3M to at

least 1M in 4Q, which remains a point to watch. In our catch-up, management

emphasized that this was driven by prudence around this population.

• On risk adjustment, management incorporated final 2025 CMS results that were

favorable to prior estimates (based on management commentary we assume ~

$150M-$200M in favorability), reinforcing confidence in its reserving process.

Given evolving market dynamics, a changing member mix, and a still-maturing

claims experience, management is prudently reestablishing the majority of that

prior-year favorability in the current-year accrual. Second-quarter ACA trend

was described as in line to slightly favorable, supported by volume and timing

dynamics.

• Medicare Advantage remains a positive, with ELV’s portfolio actions

continuing to support performance.

• MA was an outperformer in 2Q, continuing the trend from 1Q, showing the

benefit of portfolio actions taken for 2026, coupled with favorable claims

experience.